{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:30Z","timestamp":1786982730295,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40121-024-01094-y","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T21:07:31Z","timestamp":1735160851000},"page":"245-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antifungal Treatment for Japanese Patients with Chronic Pulmonary Aspergillosis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8226-9219","authenticated-orcid":false,"given":"Yoshiyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-7679","authenticated-orcid":false,"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2955-6825","authenticated-orcid":false,"given":"Masataka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-4435","authenticated-orcid":false,"given":"Kazuaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-8147","authenticated-orcid":false,"given":"Shotaro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-390X","authenticated-orcid":false,"given":"Naoki","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-2277","authenticated-orcid":false,"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-476X","authenticated-orcid":false,"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-5706","authenticated-orcid":false,"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-824X","authenticated-orcid":false,"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"1094_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00692-8","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024. https:\/\/doi.org\/10.1016\/s1473-3099(23)00692-8.","journal-title":"Lancet Infect Dis"},{"key":"1094_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-981-13-3435-1_6","volume-title":"Pulmonary aspergillosis: diagnosis and cases","author":"DN Su","year":"2019","unstructured":"Su DN, Qiu C, Lu PX, Wu SP, Song WD. Diagnosis of pulmonary aspergillosis. In: Qiu C, Lu PX, Wu SP, editors. Pulmonary aspergillosis: diagnosis and cases. Singapore: Springer Singapore; 2019. p. 15\u20136."},{"issue":"12","key":"1094_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2471\/BLT.11.089441","volume":"89","author":"DW Denning","year":"2011","unstructured":"Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ. 2011;89(12):864\u201372.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"1094_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/mmy\/myv093","volume":"54","author":"K Takeda","year":"2016","unstructured":"Takeda K, Imamura Y, Takazono T, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol. 2016;54(2):120\u20137.","journal-title":"Med Mycol"},{"issue":"3","key":"1094_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/myc.12885","volume":"62","author":"F Bongomin","year":"2019","unstructured":"Bongomin F, Maguire N, Moore CB, Felton T, Rautemaa-Richardson R. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a retrospective comparison of rates of adverse events. Mycoses. 2019;62(3):217\u201322.","journal-title":"Mycoses"},{"issue":"4","key":"1094_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193732","volume":"13","author":"F Bongomin","year":"2018","unstructured":"Bongomin F, Harris C, Hayes G, Kosmidis C, Denning DW. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS ONE. 2018;13(4):e0193732.","journal-title":"PLoS ONE"},{"key":"1094_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01062-2016","author":"D Lowes","year":"2017","unstructured":"Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.01062-2016.","journal-title":"Eur Respir J"},{"issue":"7","key":"1094_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S1473-3099(22)00057-3","volume":"22","author":"IS Sehgal","year":"2022","unstructured":"Sehgal IS, Dhooria S, Muthu V, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Lancet Infect Dis. 2022;22(7):1052\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1094_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","volume":"47","author":"DW Denning","year":"2016","unstructured":"Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45.","journal-title":"Eur Respir J"},{"issue":"5","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/cid\/ciz287","volume":"70","author":"M Tashiro","year":"2020","unstructured":"Tashiro M, Takazono T, Saijo T, et al. Selection of oral antifungals for initial maintenance therapy in chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2020;70(5):835\u201342.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1094_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00228-008-0574-7","volume":"65","author":"G Wang","year":"2009","unstructured":"Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"1094_CR12","unstructured":"Number of hospitals in DPC. Central Social Insurance Medical Council; 2022. https:\/\/www.mhlw.go.jp\/content\/12404000\/000945193.pdf. Accessed 3 Aug 2024."},{"issue":"3","key":"1094_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.37737\/ace.1.3_76","volume":"1","author":"H Yasunaga","year":"2019","unstructured":"Yasunaga H. Real world data in Japan: Chapter II the diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1(3):76\u20139.","journal-title":"Ann Clin Epidemiol"},{"key":"1094_CR14","unstructured":"Medical Data Vision Co., Ltd. What makes MDV Database Special?. https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/. Accessed 4 Oct 2024."},{"issue":"5","key":"1094_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2020.100015","volume":"1","author":"F Bongomin","year":"2020","unstructured":"Bongomin F, Otu A, Harris C, Foden P, Kosmidis C, Denning DW. Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. Clin Infect Pract. 2020;1(5):100015.","journal-title":"Clin Infect Pract"},{"issue":"10","key":"1094_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240374","volume":"15","author":"R Olum","year":"2020","unstructured":"Olum R, Baluku JB, Kazibwe A, Russell L, Bongomin F. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a systematic review and meta-analysis. PLoS ONE. 2020;15(10):e0240374.","journal-title":"PLoS ONE"},{"issue":"8","key":"1094_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/mmy\/myz003","volume":"57","author":"Y Tsuchido","year":"2019","unstructured":"Tsuchido Y, Tanaka M, Nakano S, Yamamoto M, Matsumura Y, Nagao M. Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34\/L98H mutation in the Kyoto and Shiga regions of Japan. Med Mycol. 2019;57(8):997\u20131003.","journal-title":"Med Mycol"},{"issue":"3","key":"1094_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jiac.2020.11.027","volume":"27","author":"T Takazono","year":"2021","unstructured":"Takazono T, Ito Y, Tashiro M, et al. Transition of triazole-resistant Aspergillus fumigatus isolates in a Japanese tertiary hospital and subsequent genetic analysis. J Infect Chemother. 2021;27(3):537\u20139.","journal-title":"J Infect Chemother"},{"issue":"1","key":"1094_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1128\/AAC.05394-11","volume":"56","author":"M Tashiro","year":"2012","unstructured":"Tashiro M, Izumikawa K, Minematsu A, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012;56(1):584\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1094_CR20","first-page":"204993612412537","volume":"11","author":"M Tashiro","year":"2024","unstructured":"Tashiro M, Takazono T, Izumikawa K. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges. Ther Adv Infect Dis. 2024;11:20499361241253750.","journal-title":"Ther Adv Infect Dis"},{"issue":"4","key":"1094_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12281-017-0304-7","volume":"11","author":"F Maghrabi","year":"2017","unstructured":"Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: the UK National Aspergillosis centre approach. Curr Fungal Infect Rep. 2017;11(4):242\u201351.","journal-title":"Curr Fungal Infect Rep"},{"issue":"6","key":"1094_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.resinv.2024.09.015","volume":"62","author":"Y Kimura","year":"2024","unstructured":"Kimura Y, Sasabuchi Y, Jo T, et al. Epidemiology of chronic pulmonary aspergillosis: a nationwide descriptive study. Respir Investig. 2024;62(6):1102\u20138.","journal-title":"Respir Investig"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01094-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:58:59Z","timestamp":1738198739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01094-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01094-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Saito is an employee of Datack, Inc. and has indirectly received consulting fees through Datack, Inc. from Asahi Kasei Pharma Corporation. The other authors (Masataka Yoshida, Kazuaki Takeda, Shotaro Ide, Naoki Iwanaga, Naoki Hosogaya and Noriho Sakamoto) have no conflicts of interest to declare. T. Takazono, M. Tashiro, H. Mukae, and K. Izumikawa have received lecture fees from Asahi Kasei Pharma Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Ethics Committee of the Graduate School of Biomedical Sciences, Nagasaki University, approved the study protocol (protocol no.23072802).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}